Clicky

Ultragenyx Pharmaceutical Inc.(RARE)

Description: Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Acid Rare Diseases Monoclonal Antibody Phosphates Glucose Fatty Acids Ibm Enzyme Replacement Therapy Fibroblast Growth Factor Mucopolysaccharidosis Myopathy Molecule Product Transporter Pharma Services Biologics Deficiency Syndrome Rare And Ultra Rare Diseases

Home Page: www.ultragenyx.com

RARE Technical Analysis

60 Leveroni Court
Novato, CA 94949
United States
Phone: 415 483 8800


Officers

Name Title
Dr. Emil D. Kakkis M.D., Ph.D. Founder, Pres, CEO & Director
Mr. John Richard Pinion II Chief Quality Operations Officer & Exec. VP of Translational Sciences
Dr. Camille L. Bedrosian M.D. Chief Medical Officer & Exec. VP
Mr. Erik Harris Exec. VP & Chief Commercial Officer
Mr. Theodore A. Huizenga Sr. VP, Corp. Controller & Principal Accounting Officer
Mr. Dennis Karl Huang Chief Technical Operations Officer & Exec. VP
Ms. Danielle Keatley Sr. Director of Investor Relations & Corp. Communications
Ms. Karah Herdman Parschauer J.D. Chief Legal Officer & Exec. VP
Mr. Ernie W. Meyer Chief HR Officer & Exec. VP
Mr. Thomas R. Kassberg Chief Bus. Officer & Exec. VP

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 6.7978
Price-to-Sales TTM: 9.304
IPO Date: 2014-01-31
Fiscal Year End: December
Full Time Employees: 1119
Back to stocks